Literature DB >> 5350402

Cirrhosis caused by methotrexate in the treatment of psoriasis.

S A Muller, G M Farrow, D L Martalock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5350402

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  12 in total

1.  Azathioprine in pemphigus vulgaris.

Authors:  J L Burton; M W Greaves; J Marks; R P Dawber
Journal:  Br Med J       Date:  1970-07-11

2.  Azathioprine in psoriasis.

Authors:  M W Greaves; R Dawber
Journal:  Br Med J       Date:  1970-04-25

3.  [Chromosome investigations in lymphocytes and bone marrow from long term methotrexate-treated psoriatics].

Authors:  W Sachsse; R Denk
Journal:  Arch Klin Exp Dermatol       Date:  1970

Review 4.  Hepatotoxicity of methotrexate in rheumatic diseases.

Authors:  S Kevat; M Ahern; P Hall
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

5.  Effect of methotrexate therapy in psoriatics on the Ito cells in liver biopsies, assessed by point-counting.

Authors:  D Hopwood; A Nyfors
Journal:  J Clin Pathol       Date:  1976-08       Impact factor: 3.411

6.  Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis.

Authors:  Lindsey Tilling; Sue Townsend; Joel David
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

7.  Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens.

Authors:  M G Dahl; M M Gregory; P J Scheuer
Journal:  Br Med J       Date:  1972-03-11

8.  Two methods of assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis.

Authors:  P D Hall; M J Ahern; L R Jarvis; P Stoll; M A Jenner; H Harley
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

9.  Azathioprine in treatment of bullous pemphigoid.

Authors:  M W Greaves; J L Burton; J Marks; R P Dawber
Journal:  Br Med J       Date:  1971-01-16

10.  Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio.

Authors:  S B Lanse; G L Arnold; J D Gowans; M M Kaplan
Journal:  Dig Dis Sci       Date:  1985-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.